VIP and drug design.
The following review outlines the physiological outcome of VIP and VIP gene manipulations. Previously, we reviewed the various VIP receptors associated with biological functions ranging from growth regulation, sexual function, bronchodilation, vasodilation and immune interactions to neurotrophism. VIP-based drug design is discussed below.
Gozes
Illana
I
Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel. igozes@post.tau.ac.il
Furman
Sharon
S
D000818:Animals; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000187:drug effects; D015195:Drug Design; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009479:Neuropeptides / Q000502:physiology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011471:Prostatic Neoplasms / Q000188:drug therapy; D051381:Rats; D018005:Receptors, Vasoactive Intestinal Peptide / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology* / Q000627:therapeutic use
C495401:ADCYAP1 protein, human; C495402:Adcyap1 protein, mouse; C495403:Adcyap1 protein, rat; D001993:Bronchodilator Agents; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide